CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncommon EGFR mutations. However, data on its activity a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Liping Kang, Jianliang Mai, Weiting Liang, Qihua Zou, Caiwen Huang, Yongbin Lin, Ying Liang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-02-01
Colecção:	Frontiers in Oncology
Assuntos:	NSCLC afatinib brain metastases CNS efficacy uncommon EGFR mutations
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1094195/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!